News
The day at a glance · 4 min read
Mood · Risk-On
+72
Sentiment, −100 to +100
Innovent-Pfizer Oncology Assets
12
Big Pharma & Biotech
UnitedHealth Share Price
$382.53
Payer Access & Managed Care
Key driverMajor FDA approvals and expanded payer access for obesity treatments fuel positive momentum across Big Pharma
Daily briefHealthcare· Money365.Market AI ·

FDA Approvals and Obesity Formulary Wins Drive Healthcare

Gilead wins first HDV approval, Lilly gains CVS coverage for full obesity portfolio, and Pfizer inks 12-asset oncology pact

Big Pharma & Biotech

Bullish
01GILD
Gilead Sciences ($GILD) received FDA approval on May 22, 2026, for Hepcludex injection to treat chronic hepatitis delta virus infection in adults without cirrhosis or with compensated cirrhosis, marking the first HDV treatment approved in the United States.
02LLY▲ +3.40%
Eli Lilly ($LLY) announced positive Phase 1b Heart-2 study results for Verve-102, an investigational in vivo base editing medicine designed to durably turn off the PCSK9 gene in the liver and lower blood cholesterol levels.
03PFE
Pfizer ($PFE) entered a strategic global licensing and collaboration agreement with Innovent Biologics for the research and development of 12 promising breakthrough early-stage and de novo cancer medicines, including licensing, co-development, and co-commercialization opportunities across antibody-drug conjugates with novel payloads and multi-specific antibodies.
04BMY
Bristol-Myers Squibb ($BMY) announced a strategic agreement with Anthropic on May 20, 2026, to deploy Claude AI across its research, clinical development, manufacturing, commercial, and corporate functions, moving beyond conversational tools to more advanced applications.

FDA & Regulation

Bullish
01GILD
The FDA approved Hepcludex injection for $GILD to treat chronic hepatitis delta virus infection in adults, representing the first therapy cleared for this indication.
02JNJ
Johnson & Johnson ($JNJ) announced the FDA approved a supplemental Biologics License Application to include evidence in the TREMFYA label for the inhibition of progression of structural joint damage in adults with active psoriatic arthritis, making TREMFYA the only IL-23 inhibitor proven to help stop further structural damage. Compass Pathways is advancing COMP360 psilocybin for treatment-resistant depression with Phase 3 success and expects to submit a rolling NDA by 4Q26. Regulatory momentum continues across novel mechanisms including psychedelics, gene editing therapies, and rare disease treatments.

Payer Access & Managed Care

Bullish
01UNH
$LLY shares jumped 3.4% after CVS restored Zepbound as a co-preferred option and simultaneously added Lilly's new oral obesity pill Foundayo, making Eli Lilly's full obesity medication portfolio accessible to all three of America's largest pharmacy benefit managers for the first time. This expanded formulary access significantly improves patient coverage and supports future sales growth for Lilly's obesity franchise. Meanwhile, UnitedHealth Group ($UNH) continues to attract attention after Berkshire Hathaway exited its remaining stake in the company, which trades at around $382.53 as it works through regulatory issues and implements changes including Optum Rx's transparent pharmacy benefit model. Analysts remain highly optimistic about $UNH stock prospects despite the Berkshire exit, with the company considerably outperforming its sector peers recently.

MedTech & Devices

Neutral
01ISRG
Intuitive ($ISRG), the global technology leader in minimally invasive care and pioneer of robotic-assisted surgery, announced the promotion of Global Senior Vice President Taylor Patton to Chief Commercial and Marketing Officer, effective July 1. Patton will join Intuitive's Executive Leadership Team, bringing experience from leading the company's endoluminal business. The leadership change comes as Intuitive continues to expand its surgical robotics footprint across multiple clinical applications beyond its core da Vinci platform.

Oncology & Clinical Development

Bullish
01MRK
Exelixis announced extensive upcoming presentations at the ASCO Annual Meeting in May 2026, highlighting new CABOMETYX data and pivotal zanzalintinib trials across multiple hard-to-treat cancers. The company announced a new Merck ($MRK) collaboration on the STELLAR-316 phase 3 colorectal cancer trial using MRD-guided enrollment, underscoring Exelixis' push to extend its oncology footprint beyond CABOMETYX.
02PFE
$PFE and Innovent's global collaboration encompasses a diverse portfolio of antibody-drug conjugates with novel differentiated payloads and multi-specific antibodies targeting breakthrough cancer treatments.
03REGN
Regeneron ($REGN) received a World Health Organization recommendation for investigational use of its Ebola antibody maftivimab in response to the current Bundibugyo Ebolavirus outbreak, with the most potent neutralizing antibody from Inmazeb showing broad activity against multiple Ebola species.

Looking Ahead

Bullish
MRKPFE
01
J.P. Morgan reinstated coverage on 14 large-cap biotechnology companies, arguing the sector is entering a major inflection point as pipeline successes increasingly translate into profitable and diversified commercial businesses. The ASCO Annual Meeting presentations from Exelixis and other oncology developers will provide key clinical data updates across multiple cancer indications. Compass Pathways' rolling NDA submission for COMP360 psilocybin in treatment-resistant depression expected by 4Q26 represents a potential milestone for psychedelic medicine approvals. The combination of FDA approvals, expanded payer access, and strategic partnerships signals strengthening fundamentals across healthcare subsectors.

Important Disclaimer — Not Investment Advice

Disclaimer: This article is provided by Money365.Market for general information and educational purposes only. It is not financial advice, a personal recommendation, or an inducement to buy, sell, or invest in any security or product. Capital is at risk and the value of investments can go down as well as up; past performance does not indicate future results. You should seek independent advice from an FCA-authorised adviser before making any financial decision.

Read the full disclaimer — 8 further points, including total-loss risk, our regulatory status and conflicts of interest

Nothing here is an offer or a solicitation to buy or sell anything, and reading it creates no advisory or fiduciary relationship between you and Money365.Market. Any decision you take is your own.

  • You can lose money — including all of it. Individual companies can and do fail, and some of the assets discussed can fall to zero. Only commit money you can afford to lose, and never borrow to invest on the strength of anything you read here.
  • Forecasts are opinion, not fact. Any valuation model, scenario, fair-value range, estimate or other forward-looking statement is illustrative, rests on assumptions that may prove wrong, and is never a price target, a forecast of actual outcomes, or a promise of any return.
  • Published at a point in time. Figures were believed accurate on the publication or last-updated date shown above and are not maintained afterwards; we are under no obligation to update them. Market and company data comes from third-party sources and is provided without warranty of accuracy, completeness or timeliness.
  • Automated content. This brief was compiled by an automated pipeline from validated news and market-data sources and passed through editorial and compliance checks. Automated content can still contain errors — verify anything you intend to rely on.
  • We are not regulated. Money365.Market is not authorised or regulated by the UK Financial Conduct Authority, is not registered with the U.S. Securities and Exchange Commission or FINRA as an investment adviser or broker-dealer, and is not a tax adviser. We hold no licence to give personal financial advice and do not do so.
  • Interests and independence. Money365.Market is not affiliated with, endorsed by or sponsored by any company, fund, exchange or platform mentioned, and is not paid to feature them. The author may hold positions in securities or assets discussed. The site earns revenue from advertising, subscriptions and, where labelled, affiliate links; this does not influence what we publish.
  • Your jurisdiction matters. Tax treatment, contribution limits, product availability and investor protections differ by country and can change. Speak to a qualified tax professional for tax matters, and to a locally licensed adviser if you are outside the UK.

Full terms: Disclaimer · Terms of Service · Privacy Policy